Measles, mumps, rubella, and human parvovirus B19 infections and neurologic disease

Handbook of Clinical Neurology

Volumn 121, Issue , 2014, Pages 1345-1353

  Bale, James F ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Congenital rubella syndrome; Human parvovirus; Measles; Mumps; Rubella; Subacute sclerosing panencephalitis

Indexed keywords

ARTICLE; CONGENITAL RUBELLA SYNDROME; ERYTHEMA INFECTIOSUM; HUMAN; HUMAN PARVOVIRUS B19; MEASLES; MEASLES VIRUS; MUMPS; MUMPS VIRUS; NEUROLOGIC DISEASE; PARECHOVIRUS; PATHOLOGY; RUBELLA; SUBACUTE SCLEROSING PANENCEPHALITIS; VACCINATION; VIROLOGY;

CONGENITAL RUBELLA SYNDROME; HUMAN PARVOVIRUS; MEASLES; MUMPS; RUBELLA; SUBACUTE SCLEROSING PANENCEPHALITIS;

ERYTHEMA INFECTIOSUM; HUMANS; MEASLES; MEASLES VIRUS; MUMPS; MUMPS VIRUS; NERVOUS SYSTEM DISEASES; PARVOVIRUS B19, HUMAN; RUBELLA; VACCINATION;

EID: 84890840374     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-7020-4088-7.00091-2     Document Type: Chapter

References (78)

1. Aicardi J., Goutieres F., Arsenio-Nunes M.L., et al. Acute measles encephalitis in children with immunosuppression. Pediatrics 1977, 59:232-239.
2. Akram M., Naz F., Malik A., et al. Clinical profile of subacute sclerosing pancephalitis. J. Coll. Physicians Surg. Pak. 2008, 18:485-488.
3. Al-Khan A., Caligiuri A., Apuzzio J. Parvovirus infections during pregnancy. Infect. Dis. Obstet. Gynecol. 2003, 11:175-179.
4. American Academy of Pediatrics Committee on Infectious Diseases. Recommended immunization schedules for children and adolescents - United States, 2008. Pediatrics 2008, 121:219-220.
5. American Academy of Pediatrics Mumps. Red Book: 2009 Report of the Committee on Infectious Diseases 2009, 470. American Academy of Pediatrics, Elk Grove Villiage, IL. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
6. American Academy of Pediatrics Parvovirus B19. Red Book: 2009 Report of the Committee on Infectious Diseases 2009, 491-492. American Academy of Pediatrics, Elk Grove Villiage, IL. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
7. American Academy of Pediatrics Committee on Infectious Diseases Vitamin A treatment of measles. Pediatrics 1993, 91:1014-1015.
8. Anderson M.J., Jones S.E., Fisher-Jock S.P., et al. Human parvovirus, the cause of erythema infectiosum (Fifth disease)?. Lancet 1983, 1:1378.
9. Aydin O.F., Senbil N., Kuyucu N., et al. Combined treatment with subcutaneous interferon-alpha, oral isoprinosine, and lamivudine for subacute sclerosing panencephalitis. J. Child Neurol. 2003, 18:104-108.
10. Bale J.F., Fujinami R. Subacute sclerosing pancephalitis. Neurotropic Virus Infections 2008, 26-34. Cambridge University Press, Cambridge. C.R. Reiss (Ed.).
11. Barlow W.E., Davis R.L., Glasser J.W., et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N. Engl. J. Med. 2001, 345:656-661.
12. Bray P.F. Mumps: a cause of hydrocephalus?. Pediatrics 1972, 49:446-449.
13. Brismar J., Gascon G.G., von Steyern K.V., et al. Subacute sclerosing panencephalitis: evaluation with CT and MR. AJNR Am. J. Neuroradiol. 1996, 17:761-772.
14. Buchanan R., Bonthius D.J. Measles virus and associated central nervous system sequelae. Semin. Pediatr. Neurol. 2012, 19:107-114.
15. Centers for Disease Control Measles prevention. MMWR 1987, 36:423-425.
16. Centers for Disease Control Progress Toward Control of Rubella and Prevention of Congenital Rubella Syndrome - Worldwide, 2009 2010, Accessed 12/24/2010. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5940a4.htm#tab.
17. Centers for Disease Control Parvovirus B19 (Fifth Disease) 2010, Accessed 122/24/2010. http://www.cdc.gov/ncidod/dvrd/revb/respiratory/parvo_b19.htm.
18. Connolly J.H., Hutchinson W.M., Allen I.V., et al. Carotid artery thrombosis, encephalitis, myelitis, and optic neuritis associated with rubella virus infections. Brain 1975, 95:583-594.
19. Croxson M.C., Anderson N.E., Vaughan A.A., et al. Subacute measles encephalitis in an immunocompetent adult. J. Clin. Neurosci. 2002, 9:600-604.
20. Dayan G.H., Guinlisk M.P., Parker A.A., et al. Recent resurgence of mumps in the United States. N. Engl. J. Med. 2008, 358:1580-1589.
21. Demir E., Aksoy A., Anlar B., et al. Atypical presentations of SSPE: a clinic study in four cases. Turk. J. Pediatr. 2007, 49:295-300.
22. Desmond M.M., Wilson G.S., Melnick J.L., et al. Congenital rubella encephalitis: course and early sequelae. J. Pediatr. 1967, 71:311-331.
23. Douvoyiannis M., Litman N., Goldman D.L. Neurological manifestations associated with parvovirus B19 infections. Clin. Infect. Dis. 2009, 48:1713-1723.
24. Dudgeon J.A. Congenital rubella. J. Pediatr. 1975, 87:1078-1086.
25. Ekstrand J.J., Herbener A., Rawlings J., et al. Heightened neurological complications in children with pandemic H1N1 infections. Ann. Neurol. 2010, 68:762-768.
26. Eroglu E., Gokcil Z., Bek S., et al. Long-term follow-up of patients with adult-onset subacute sclerosing pancephalitis. J. Neurol. Sci. 2008, 275:113-116.
27. Figueiredo C.A., Klautau G.B., Afonso A.M., et al. Isolation and genotype analysis of rubella virus from a case of Guillain-Barré syndrome. J. Clin. Virol. 2008, 43:343-345.
28. Gabay J.E., Mayers M. Ocular manifestations of systemic infections. Curr. Opin. Ophthalmol. 1997, 8:74-80.
29. Gascon G.G. Subacute sclerosing panencephalitis. Semin Pediatr Neurol 1996, 3:260-269.
30. Gascon G.G., the International Consortium on Subacute Sclerosing Panencephalitis Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study. J. Child Neurol. 2003, 18:819-827.
31. Gendelman H.E., Wolinsky J.S., Johnson R.T., et al. Measles encephalomyelitis: lack of evidence of viral invasion of the central nervous system and quantitative study of the nature of demyelination. Ann. Neurol. 1984, 15:353-360.
32. Ginsberg T., Glasky A.J. Inosiplex: an immunomodulation model for the treatment of viral disease. Ann. N. Y. Acad. Sci. 1977, 284:128-138.
33. Gregg N.M. Congenital cataract following German measles in the mother. Trans. Ophthalmol. Soc. Aust. 1941, 3:34-45.
34. Gutierrez J., Issacson R.S., Koppel B.S. Subacute sclerosing panencephalitis: an update. Dev. Med. Child Neurol. 2010, 52:901-907.
35. Hashimoto H., Fujioka M., Kinumaki H. An office-based prospective study of mumps deafness. Pediatr. Infect. Dis. J. 2009, 28:173-175.
36. Hatchette T., Davidson R., Clay S., et al. Laboratory diagnosis of mumps in a partially immunized population: the Nova Scotia experience. Can J Infect Dis Med Microbiol 2009, 20:e157-e162.
37. Herman K.L. Rubella in the United States: toward a strategy for disease control and prevention. Epidemiol. Infect. 1991, 107:55-61.
38. Honarmand S., Glaser C.A., Chow E., et al. Subacute sclerosing panencephalitis in the differential diagnosis of encephalitis. Neurology 2004, 63:1489-1493.
39. Huttenlocher P.R., Mattson R.H. Isoprinosine in subacute sclerosing panencephalitis. Neurology 1979, 29:764-771.
40. Hviid A., Rubin S., Mühlemann K. Mumps. Lancet 2008, 371:932-944.
41. Institute of Medicine Immunization safety review: vaccines and autism 2004, National Academy of Sciences, Washington DC.
42. Jabbour J.T., Duenas D.A., Sever J.L., et al. Epidemiology of subacute sclerosing panencephalitis (SSPE): a report of the SSPE Registry. JAMA 1972, 220:959-962.
43. Johnson R.T. Viral Infections of the Nervous System 1998, Lippincott-Raven, New York. 2nd edn.
44. Johnson R.T., Griffin D.E., Hirsch R.L., et al. Measles encephalomyelitis: clinical and immunologic studies. N. Engl. J. Med. 1984, 310:137-141.
45. Kanra G., Kara A., Cengiz A.B., et al. Mumps meningoencephalitis effect on hearing. Pediatr. Infect. Dis. J. 2002, 21:1167-1169.
46. Kerr J.R., Barah F., Chiswick M.L., et al. Evidence for the role of demyelination, HLA-DR alleles, and cytokines in the pathogenesis of parvovirus B19 meningoencephalitis and its sequelae. J. Neurol. Neurosurg. Psychiatry 2002, 73:739-746.
47. Koskiniemi M., Donner M., Petta O. Clinical appearance and outcome in mumps encephalitis in children. Acta Paediatr Scand 1983, 72:603-609.
48. Koskiniemi M., Rautonen J., Lehtokoski-Lehtinieme E., et al. Epidemiology of encephalitis in children: a 20 year survey. Ann. Neurol. 1991, 29:492-497.
49. La Piana F.G., Tso M.O., Jenis E.H. The retinal lesions of subacute sclerosing panencephalitis. Ann. Ophthalmol. 1974, 6:603-610.
50. Lum G.B., Williams J.P., Dyken P.R., et al. Magnetic resonance and CT imaging correlated with clinical status in SSPE. Pediatr. Neurol. 1986, 2:75-79.
51. Morellis P., Besstetti G., Longhi E., et al. Persistent parvovirus B9-induced anemia in an HIV-infected patient under HAART. Case report and review of the literature. Eur. J. Clin. Microbiol. Infect. Dis. 2007, 26:833-837.
52. Murphy J.V., Yunis E.J. Encephalopathy following measles infection in children with chronic illness. J. Pediatr. 1976, 88:937-942.
53. Mustafa M.M., Weitman S.D., Winick N.J., et al. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin. Infect. Dis. 1993, 16:654-660.
54. Parez N., Dehée A., Michel Y., et al. Papular-purpuric gloves and socks syndrome associated with B19V infection in a 6-year-old child. J. Clin. Virol. 2009, 44:167-169.
55. Peltola H., Kulkarni P.S., Kapre S.V., et al. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin. Infect. Dis. 2007, 45:459-466.
56. Robinson J., Lemay M., Vaudry W.L. Congenital rubella after anticipated maternal immunity: two cases and a review of the literature. Pediatr. Infect. Dis. J. 1994, 13:812-815.
57. Servant-Delmas A., Lefrère J.J., Morinet F., et al. Advances in human B19 erythrovirus biology. J. Virol. 2010, 84:9658-9665.
58. Singer C., Lang A.E., Suchowersky O. Adult-onset subacute sclerosing panencephalitis: case reports and review of literature. Mov. Disord. 1977, 12:342-353.
59. Slavov S.N., Kashima S., Pinto A.C., et al. Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions. FEMS Immunol. Med. Microbiol. 2011, 62:247-262.
60. Sonmez F.M., Odemis E., Ahmetoglu A., et al. Brainstem encephalitis and acute disseminated encephalomyelitis following mumps. Pediatr. Neurol. 2004, 30:132-134.
61. Sudfeld C.R., Navar A.M., Halsey N.A. Effectiveness of measles vaccination and vitamin A treatment. Int. J. Epidemiol. 2010, 39:i48-i55.
62. Tatli B., Ekici B., Ozmen M. Current therapies and future perspectives in subacute sclerosis panencephalitis. Expert Rev. Neurother. 2012, 12:485092.
63. Ternavasio-de la Vega H.G., Boronat M., Ojeda A., et al. Mumps orchitis in the post-vaccine era (1967-2009): a single-center series of 67 patients and review of clinical outcome and trends. Medicine (Baltimore) 2010, 89:96-116.
64. Tipples G., Hiebert J. Detection of measles, mumps and rubella viruses. Methods Mol. Biol. 2011, 665:183-193.
65. Townsend J.J., Baringer J.R., Wolinsky J.S., et al. Progressive rubella panencephalitis: late onset after congenital rubella. N. Engl. J. Med. 1975, 292:990-993.
66. Trivedi R., Gupta R.K., Agarawal A. Assessment of white matter damage in subacute sclerosing panencephalitis using quantitative diffusion tensor MR imaging. AJNR Am. J. Neuroradiol. 2006, 27:1712-1716.
67. Ueda K., Nishida Y., Oshima K., et al. Congenital rubella syndrome: correlation of gestational age at time of maternal rubella with type of defect. J. Pediatr. 1979, 94:763-765.
68. Wang Y., Cao K., Yang W., et al. Bilateral total deafness due to mumps and outcome of cochlear implantation. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2003, 17:602-603.
69. Wierenga K.J., Serjeant B.E., Serjeant B.R. Cerebrovascular complications and parvovirus infections in homozygous sickle cell disease. J. Pediatr. 2001, 139:438-442.
70. Wild N.J., Sheppard S., Smithelis R.W., et al. Onset and severity of hearing loss due to congenital rubella. Arch. Dis. Child. 1989, 64:1280-1283.
71. World Health Organization (WHO) Mumps vaccine. Wkly. Epidemiol. Rec. 2007, 82:49-60.
72. World Health Organization (WHO) (2012a). Accessed 10/29/2012. http://www.who.int/mediacentre/factsheets/fs286/en/index.html.
73. World Health Organization (WHO) (2012b). Accessed 10/29/2012 http://www.who.int/immunization_monitoring/diseases/mumps/en/.
74. World Health Organization (WHO) (2012c). Accessed 10/29/2012. http://www.who.int/immunization_monitoring/diseases/Rubella_map_schedule.jpg.
75. World Health Organization (WHO) (2013). Accessed 10/22/2013. http://:www.who.int/mediacentre/factsheets/fs286/en.
76. Yamaoka Y., Isozaki E., Kagamihara Y., et al. A case of Guillain-Barré syndrome following human parvovirus B19 infection. Rinsho Shinkeigaku 2000, 40:471-475.
77. Yamashita Y., Matsuishi T., Murakami, et al. Neuroimaging findings (ultrasonography, CT, MRI) in 3 infants with congenital rubella syndrome. Pediatr. Radiol. 1991, 21:547-549.
78. Yilmaz K., Yilmaz M., Mete A., et al. A correlative study of FDG PET, MRI/CT, electroencephalography, and clinical features in subacute sclerosing panencephalitis. Clin. Nucl. Med. 2010, 35:675-681.